| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14740338.2015.1108961 |
| P698 | PubMed publication ID | 26559664 |
| P50 | author | Itishree Trivedi | Q59703376 |
| P2093 | author name string | Stephen B Hanauer | |
| P2860 | cites work | Natalizumab Induction and Maintenance Therapy for Crohn's Disease | Q22250890 |
| Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 | ||
| Adverse effects of biologics: a network meta-analysis and Cochrane overview | Q24234197 | ||
| Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab | Q26851341 | ||
| Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases | Q26864098 | ||
| Review article: anti-adhesion therapies for inflammatory bowel disease | Q26999705 | ||
| Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 | ||
| Natalizumab for active Crohn's disease | Q28201431 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease | Q28213091 | ||
| Golimumab for the treatment of ulcerative colitis | Q28236322 | ||
| Certolizumab pegol for the treatment of Crohn's disease | Q28236746 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease | Q48484232 | ||
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial | Q49167560 | ||
| Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. | Q50898166 | ||
| Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. | Q51036254 | ||
| Serum adalimumab concentration and clinical remission in patients with Crohn's disease. | Q51069789 | ||
| Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. | Q51553118 | ||
| Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. | Q51554698 | ||
| Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. | Q51739537 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. | Q53477555 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Autoimmune Diseases Induced by TNF-Targeted Therapies | Q56907567 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Infliximab prevents Crohn's disease recurrence after ileal resection | Q57130823 | ||
| Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease | Q57265393 | ||
| Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis | Q57910344 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. | Q47827799 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. | Q48172806 | ||
| Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience | Q48314202 | ||
| Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
| Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies | Q28256960 | ||
| A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease | Q28270722 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial | Q28296771 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death | Q29620519 | ||
| Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. | Q30679247 | ||
| Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy | Q33401933 | ||
| Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 | ||
| Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis | Q33756929 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| The clinical features of PML. | Q34085230 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy | Q34275329 | ||
| Vedolizumab as induction and maintenance therapy for ulcerative colitis | Q34365566 | ||
| Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 | ||
| Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial | Q34431219 | ||
| A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease | Q34520640 | ||
| The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients | Q34544307 | ||
| Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 | ||
| Management of Crohn's disease in adults. | Q34931424 | ||
| Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis | Q35171236 | ||
| Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials | Q35177220 | ||
| Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival | Q35359125 | ||
| A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease | Q36078334 | ||
| Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry | Q36223905 | ||
| Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation | Q36465773 | ||
| A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis | Q36720362 | ||
| Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions | Q36740090 | ||
| Biologics in Crohn's disease: searching indicators for outcome | Q36909385 | ||
| Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults | Q37035957 | ||
| Tumor necrosis factor antagonist mechanisms of action: a comprehensive review | Q37043901 | ||
| Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. | Q37240622 | ||
| Comparative effectiveness of infliximab and adalimumab for Crohn's disease | Q37445629 | ||
| Anti-TNF-induced lupus | Q37471071 | ||
| Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review | Q37560336 | ||
| Clinical implications of mucosal healing for the management of IBD. | Q37641754 | ||
| A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease | Q37796190 | ||
| Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis | Q37853359 | ||
| Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab | Q37982013 | ||
| Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms | Q37987352 | ||
| Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis | Q38059422 | ||
| Progressive multifocal leukoencephalopathy in patients with multiple sclerosis | Q38089536 | ||
| Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. | Q38131826 | ||
| Demyelination and other neurological adverse events after anti-TNF therapy | Q38137583 | ||
| Treat to target: a proposed new paradigm for the management of Crohn's disease | Q38137614 | ||
| Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol | Q38200926 | ||
| Update on anti-tumor necrosis factor agents in Crohn disease | Q38238708 | ||
| Converging goals of treatment of inflammatory bowel disease from clinical trials and practice | Q38240237 | ||
| Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study | Q38425063 | ||
| Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis | Q38551323 | ||
| Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial | Q39742714 | ||
| Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort | Q40186159 | ||
| Increased risk for demyelinating diseases in patients with inflammatory bowel disease. | Q40391419 | ||
| Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells | Q40836468 | ||
| Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages | Q40875345 | ||
| Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis | Q43553836 | ||
| Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study | Q43731459 | ||
| Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Restaurantmanhaj's | Q43778384 | ||
| Rising incidence of inflammatory bowel disease among children: a 12-year study | Q44075741 | ||
| Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial | Q44151825 | ||
| Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival | Q44671543 | ||
| Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. | Q44702374 | ||
| Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 | ||
| Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy | Q44771716 | ||
| The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies | Q44803722 | ||
| Still in pursuit | Q45194269 | ||
| High prevalence of inflammatory bowel disease in United States residents of Indian ancestry | Q45326837 | ||
| Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease | Q45329439 | ||
| Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis | Q45734256 | ||
| Adalimumab-induced autoimmune hepatitis. | Q45932142 | ||
| A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease | Q46230892 | ||
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis | Q46286038 | ||
| Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis | Q46400709 | ||
| Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial | Q46533213 | ||
| Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin | Q46549276 | ||
| Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial | Q46688826 | ||
| Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers | Q46763092 | ||
| Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed | Q46835906 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 1915-1934 | |
| P577 | publication date | 2015-11-11 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases | |
| P478 | volume | 14 |
Search more.